

Our journey | Dr. Reddy's has evolved from being an API manufacturer to a global pharmaceutical company















1990-1995

1995-2000

2001-2005

2005-2010

2010-2015

2015-2020

2020 Onwards

Moving from an entrepreneurial to a professional organization

Building worldclass capabilities

Building a lasting lnstitution

Globalizing and growing inorganically

Product centric to Patient centric Organization

Execution
Excellence &
Cost focus

Scaling to New Horizons



Leadership crisis (1990)

~70% of the employees resigned the day I joined the company

Macroeconomic crisis (1998)

Financial crisis in Russia — one of our leading markets globally

Overseas acquisition that didn't go as expected (2006)

Acquiring a leading generics company in Germany.

Largest by an Indian company* overseas

Challenges of operations safety and Quality (2015)

Injuries and US FDA Warning letter

4

^{*} Outside of oil and gas at that time



Leadership crisis

The day I joined, more than 70 percent of the employees had quit their jobs and left the company!



Key learnings from the crisis

The river lasts many times longer than the individual drops of water it comprises — the company must be stronger than the few individuals who run it

The company should be designed to thrive through change: change in owners, employees, products, technology over a period of time

1990-1995 | Moving from an entrepreneurial to a professional organization

FROM

- Hierarchical
- Need to know
- Largely local employee base
- Command & control
- **Entrepreneur led**

TO

Egalitarian

CULTURE SHIFT

- Open & transparent
- Global recruitment
- Values led empowered culture
- Professional meritocracy



1995-2000 Building competitiveness through capabilities

Regulatory, IP, Quality, Manufacturing, Legal, SH&E

Industry leading chemistry skills

Niche product opportunities, Global R&D network Early mover advantage in biosimilars

4 biosimilar products being marketed

Biologics development and manufacturing in India

Breaking ground with differentiated formulations

4 NDAs filed in the US; 2 products launched

Strong pipeline of products under development

Vertical integration


Integrated R&D, API manufacturing (10 facilities) & formulations manufacturing (15 facilities)




Macroeconomic crisis in Russia

Russia through the years has witnessed several impacts. Dr. Reddy's has consistently invested over the last three decades to become a leading branded generics player in Russia.

Dr. Reddy's has consistently invested in Russia over the last 3 decades to become the #1 ranked Indian generics company







Key learnings from the crisis


Clarity of purpose – the reason for which a company exists, and the awareness of its identity allows it to make the right choices and invest in the long term

 Companies that survive for a long time exist in a world that keeps changing and cannot be controlled. Learning and adapting to change is essential for success

2000-2005 | Building a lasting institution through professional talent & strong governance

- Full P&L Leaders
- Hire the best
- Devolved Decision Making
- Process-orientation
- Transparency

Board as a strategic resource





2005-2010 | Growing the organization through global acquisitions & partnerships

- Betapharm (DE)
- Manufacturing sites in Mexico, US, UK





Overseas acquisition

German government amended the market to a tender based supply of drugs, rendering the intangible assets and goodwill of the acquisition (the sales force and existing brand) worthless



Key learnings from the crisis

Resilient companies do not risk their capital gratuitously. Money in the bank is important. Financial prudence allows them to govern their wealth and evolution.

 Transparent corporate governance, having strong tolerance to setbacks and the ability to rebound helps companies to live beyond crisis

2010-2015 | Product centric to a patient centric organization



Realigning ourselves to better articulate our purpose & promises, keeping patient centricity at the core of what we do



Operations safety and Quality



World

Busines:

arkets Breakingviews

Video

More

ONEY NEWS NOVE

NOVEMBER 6, 2015 / 10:53 AM / UPDATED 7 YEARS AGO

Dr Reddy's hit by FDA warning, shares fall 15 percent

By Zeba Siddiqui

4 MIN READ



MUMBAI (Reuters) - Dr Reddy's Laboratories Ltd, India's second-largest drugmaker, has received a "warning letter" from U.S. regulators over inadequate quality controls at three manufacturing plants producing drugs for cancer and other diseases.

The warning is the latest in a string of incidents that have hurt the industry's reputation and slowed its growth in the world's largest drug market, where India supplies more than 40 percent of the generic and over-the-counter medicines.



Key learnings from the crisis

Companies that aim to live long cannot be complacent. They need to be sensitive to the world around them and continuously improve their systems

 Living companies have a culture of doing things the right way and encourage people to behave in alignment with their core values

2015-2020 Operational and execution excellence

Simplify processes, improve on capabilities & differentiate in the marketplace and fulfil our promises to patients and partners



"I want to build a company that will last 500 years"

- Dr. K Anji Reddy






Our Purpose

We accelerate access to affordable and innovative medicines because

Good Health Can't Wait.

Our Purpose translates into three pillars

Operational excellence and productivity to deliver care affordably to patients



To serve as many patients as possible across the world

Focused innovation to identify and address unmet needs of patients

Deep Science & technology

Progressive People Practices

Good Governance

Our Sustainability goals

Being committed to environmental stewardship

Reducing carbon emissions

- 100% renewable power (RE100) by 2030
- Carbon neutral in direct operations by 2030
- 12.5% reduction in indirect carbon emissions (Scope 3) by 2030

Water Positivity

Water-positive by 2025

Making our products accessible and affordable for patients

Access

Serve 1.5Bn+ patients by 2030

Affordability

• 25% new launches to be first to market by 2027

Innovation

• 3 Innovative products improving standard of treatment every year

Contributing to a fairer and more socially inclusive world

Equity, diversity and inclusion

- At least 35% women in senior leadership (3X from current) by 2030
- Gender parity by 2035
- 3% of our workforce to be PwD by 2030
- Ensure 100% living wages for our extended workforce by 2025

Enhancing trust with our stakeholders

Highest standards on Compliance and Ethics backed by robust Corporate Governance

ESG disclosures: Enhance disclosure to reach top quartile by 2025

Strategic Suppliers: 100% of our strategic suppliers to be compliant with our internal ESG framework by 2030

Our Promises bring our purpose to life

- Bringing expensive medicines within reach
- Addressing unmet patient meets
 - Helping patients manage disease better
- Working with partners to help them succeed
 - Enabling and helping our partners ensure that our medicines are available where needed

Key lessons to build a resilient living company



Be fiscally prudent

Companies that survive longer show financial prudence to govern their growth and evolution



Adapt and be agile

Companies which continue to invest in learning, survive in a changing world that cannot be controlled



Clarity of purpose and values

Companies that live longer are aware of their identity and have a clear purpose to exist



People and community building

Companies that focus on building community where both entity and individual care about each other builds loyalty and increases longevity



Loosening Steering and Control

Companies that live longer must give people the space to develop ideas. They must have some freedom from control, from direction, and from punishment for failures.



Companies stand better chance of surviving and living long in a changing world

Thank you

